@article{3029992,
    title = "The efficacy and tolerability of tetracyclines and clindamycin plus
rifampicin for the treatment of hidradenitis suppurativa: Results of a
prospective European cohort study",
    author = "van Straalen, Kelsey R. and Tzellos, Thrasyvoulos and Guillem, Phillipe and and Benhadou, Farida and Cuenca-Barrales, Carlos and Daxhelet, Mathilde and and Daoud, Mathieu and Efthymiou, Ourania and Giamarellos-Bourboulis, and Evangelos J. and Jemec, Gregor B. E. and Katoulis, Alexandros C. and and Koenig, Anke and Lazaridou, Elizabeth and Marzano, V, Angelo and and Matusiak, Lucas and Molina-Leyva, Alejandro and Moltrasio, Chiara and and Pinter, Andreas and Potenza, Concetta and Romani, Jorge and Saunte, and Ditte M. and Skroza, Nevena and Stergianou, Dimitra and Szepietowski, and Jacek and Trigoni, Anastasia and Vilarrasa, Eva and van der Zee, Hessel and H.",
    journal = "Journal of the American Academy of Dermatology",
    year = "2021",
    volume = "85",
    number = "2",
    pages = "369-378",
    publisher = "MOSBY-ELSEVIER",
    issn = "0190-9622, 1097-6787",
    doi = "10.1016/j.jaad.2020.12.089",
    keywords = "acne inversa; antibiotics; clindamycin; doxycycline; efficacy;
guideline; minocycline; outcome; rifampicin; tetracycline; therapy;
treatment",
    abstract = "Background: Tetracyclines and clindamycin plus rifampicin combination
therapy are both considered first-line therapy in current hidradenitis
suppurativa guidelines. However, evidence for their efficacy is drawn
from small studies, often without validated outcomes.
Objective: To assess the 12-week efficacy of oral tetracyclines and a
combination of clindamycin and rifampicin. Methods: A prospective,
international cohort study performed between October 2018 and August
2019.
Results: In total, 63.6% of the included 283 patients received oral
tetracyclines, and 36.4% were treated with clindamycin and rifampicin.
Both groups showed a significant decrease in International Hidradenitis
Suppurativa Severity Score System from baseline (both P < .001). The
Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in
40.1% and 48.2% of patients, respectively (P = .26). Patient
characteristics or disease severity were not associated with the
attainment of HiSCR or the minimal clinically important differences for
the Dermatology Life Quality Index and pain.
Limitations: Cohort study. Respectively, 23.9% and 19.4% of patients
had to be excluded from the HiSCR analysis for the tetracycline and
combination therapy group because of a low abscess and nodule count at
baseline.
Conclusion: This study shows significant efficacy of both tetracycline
treatment and clindamycin and rifampicin combination therapy after 12
weeks in patients with hidradenitis suppurativa. No significant
differences in efficacy were observed between the 2 treatments,
regardless of disease severity."
}